Evidence map›Paper›PMID 39570925›Full record

ArticleRevista medica del Instituto Mexicano del Seguro Social2024

[Clostridiodes difficile bacteraemia. First mexican case report].

Iván González-Godínez, Edgar Carrillo-Vázquez, Ana Laura Garduño-Ortíz, Sebastián Enrique Chacón-Hernández, Homero Antonio Hevia-Del Cabrera

Abstract readCase ReportsEnglish Abstract
In one paragraph

Article in Revista medica del Instituto Mexicano del Seguro Social, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Iván González-GodínezInstituto Mexicano del Seguro Social, Centro Médico Nacional Siglo XXI, Hospital de Especialidades "Dr. Bernardo Sepúlveda Gutiérrez", Servicio de Infectología. Ciudad de México, México.ORCID 0000-0003-0917-638X
Edgar Carrillo-VázquezInstituto Mexicano del Seguro Social, Centro Médico Nacional Siglo XXI, Hospital de Especialidades "Dr. Bernardo Sepúlveda Gutiérrez", Servicio de Infectología. Ciudad de México, México.ORCID 0009-0005-0112-6195
Ana Laura Garduño-OrtízInstituto Mexicano del Seguro Social, Centro Médico Nacional Siglo XXI, Hospital de Especialidades "Dr. Bernardo Sepúlveda Gutiérrez", Laboratorio de Microbiología. Ciudad de México, México.ORCID 0009-0002-5902-6398
Sebastián Enrique Chacón-HernándezInstituto Mexicano del Seguro Social, Hospital General de Zona No. 47 "Vicente Guerrero", Servicio de Medicina Interna. Ciudad de México, México.ORCID 0009-0000-0197-5588
Homero Antonio Hevia-Del CabreraInstituto Mexicano del Seguro Social, Hospital General de Zona No. 47 "Vicente Guerrero", Servicio de Medicina Interna. Ciudad de México, México.ORCID 0009-0007-6991-5531

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Clostridiodes difficile bacteremia (CDB) develops in less than 1% of all the cases, nonetheless, with a significant increase in mortality. The objective of the present article is to report the first case of CDB in the Mexican population, empathizing with the treatment difficulty derived from the lack of consensus. Clinical case: A 42-year-old female with previous history of chronic thromboembolic pathologies and grade III obesity, develops community acquired atypical pneumonia requiring hospitalization, having parenteral antibiotics. During hospitalization, non severe C. difficile infection was concluded and started treatment with Vancomycin for 10 days. One week later the patient presented to the emergency department at HES CMN SXXI with gastrointestinal symptomatology, mostly epigastric pain, fever and diarrhea. After proper approach, C. difficile was isolated in blood cultures through mass spectrophotometry analysis, for which a 10-day treatment of metronidazole was prescribed with resolution of the infection being discharged afterwards. Conclusions: CDB is an exceptional and lethal clinical condition, mainly seen in patients with previous gastrointestinal diseases. IV Metronidazole demonstrated therapeutic efficacy in this case report and could be a successful and available therapeutic option in Mexican health care units.

Indexed as

BacteremiaClostridioides difficileClostridium InfectionsAdultFemaleHumansMexicoBacteremiaConsensusDiarrheaInfections

Identifiers

PMID39570925
PMCPMC12551965

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.